The androgen receptor CAG repeat length polymorphism associates with prostate volume in Finnish men with benign prostatic hyperplasia.
The development of benign prostatic hyperplasia requires the presence of testicular androgens during prostate development, puberty, and ageing. We thus examined the association of three polymorphisms, namely, CYP3A5 6986A>G, CYP19A1 1531C>T, and androgen receptor (AR) gene CAG repeat length, which have previously been linked to the androgen pathway and with clinical characteristics of benign prostatic hyperplasia. Tissue samples from 262 consecutive prostate operations were used for genotyping. Prostate volumes and prostate-specific antigen values were collected from patient records. Linear regression analysis was performed to study the polymorphisms in an age-adjusted model. We did not find any association between the CYP3A5 6986A>G polymorphism and clinical characteristics of benign prostatic hyperplasia. Further, the previously published CYP19A1 1531C>T polymorphism association with an enlarged prostate could not be confirmed with this material. However, we detected an association between short AR gene CAG repeat length and a small prostate volume, which confirms a previous finding in the Finnish population. The data presented suggest a negligible role for the CYP3A5 6986A>G polymorphism in benign prostate enlargement in the Finnish population. However, the results presented do provide further evidence for potentially different genetic mechanisms behind benign prostatic hyperplasia in Finnish and other Caucasian populations. This is based on the conflicting results for AR gene CAG repeat length associations with benign prostatic hyperplasia found in published works.
Renko
Outi
O
Department of Pathology, University of Oulu, Oulu, Finland.
Savolainen
Eeva-Riitta
ER
Loikkanen
Ildikó
I
Paavonen
Timo K
TK
Vaarala
Markku H
MH
D000367:Age Factors; D000368:Aged; D005387:Finland; D006801:Humans; D008297:Male; D008875:Middle Aged; D009929:Organ Size / Q000235:genetics; D011110:Polymorphism, Genetic; D011379:Prognosis; D011467:Prostate / Q000473:pathology*; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology*; D011944:Receptors, Androgen / Q000235:genetics*; D018911:Trinucleotide Repeats / Q000502:physiology*
C410798:AR protein, human; D011944:Receptors, Androgen